US stock · Healthcare sector · Biotechnology
Company Logo

Apellis Pharmaceuticals, Inc.

APLSNASDAQ

68.41

USD
-0.23
(-0.34%)
Market Closed
-10.54P/E
-15Forward P/E
-0.51P/E to S&P500
7.516BMarket CAP
- -Div Yield
Upcoming Earnings
7 Nov-11 Nov
Shares Short
7/29/22
9.84M
Short % of Float
12.61%
Short % of Shares Outs.
9.21%
% Held by Insiders
15.19%
% Held by Institutions
88.43%
Beta
1.54
PEG Ratio
-0.34
52w. high/low
69.45/27.50
Avg. Daily Volume
1.08M
Return %
Stock
S&P 500
1 year
21.34
(3.63)
3 years
147.71
49.25
5 years
- -
74.02
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
24.17
12.45
32.00
11.45
33.18
12.50
58.03
16.85
73.00
27.50
69.45
33.32
Currency: USD
- -
- -
- -
- -
- -
- -
- -
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.33
0.89
1.05
Earnings per share
- -
- -
- -
- -
- -
- -
- -
(0.22)
(0.60)
(2.57)
(1.51)
(3.68)
(2.34)
(4.90)
(4.59)
(9.93)
(7.02)
FCF per share
- -
- -
- -
- -
- -
- -
- -
(0.19)
(0.55)
(1.04)
(1.44)
(3.36)
(2.41)
(3.42)
(2.21)
(7.51)
(6.66)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
- -
- -
0.00
- -
- -
- -
- -
0.03
0.07
0.01
0.01
Book Value per sh.
- -
- -
- -
- -
- -
- -
- -
0.25
0.73
1.93
1.32
10.74
2.96
0.55
2.72
2.64
2.55
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
- -
18
18
18
18
14
54
62
75
75
92
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(4.4)
(8.3)
(4.6)
(7.5)
(5.0)
(10.5)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.2)
(0.3)
(0.2)
(0.2)
(0.2)
(0.5)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
251
67
97
Operating margin
- -
- -
- -
- -
- -
- -
- -
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(85.3)%
(805.7)%
(1,055.4)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
- -
0
0
- -
- -
0
- -
0
1
1
1
Net profit (m)
- -
- -
- -
- -
- -
- -
- -
(4)
(11)
(47)
(27)
(51)
(128)
(305)
(345)
(746)
(638)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
3.9%
- -
- -
- -
- -
- -
(0.5)%
(0.0)%
(0.4)%
Net profit margin
- -
- -
- -
- -
- -
- -
- -
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(137.6)%
(1,121.3)%
(1,407.1)%
Working capital (m)
- -
- -
- -
- -
- -
- -
- -
5
13
35
24
175
185
307
789
692
833
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
26
25
143
359
206
189
Equity (m)
- -
- -
- -
- -
- -
- -
- -
5
13
35
24
149
161
34
205
199
334
ROIC
- -
- -
- -
- -
- -
- -
- -
(89.1)%
(82.0)%
18.3%
(114.7)%
(28.9)%
(67.1)%
(89.0)%
(37.8)%
(97.8)%
(70.4)%
Return on capital
- -
- -
- -
- -
- -
- -
- -
(77.5)%
(78.9)%
16.8%
(99.4)%
(27.9)%
(61.5)%
(74.0)%
(32.6)%
(83.1)%
(61.3)%
Return on equity
- -
- -
- -
- -
- -
- -
- -
(87.6)%
(81.6)%
(133.0)%
(114.0)%
(34.2)%
(79.2)%
(890.2)%
(168.6)%
(375.7)%
(190.9)%
Plowback ratio
- -
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
8 Aug · 2022 | Q2
All numbers in millions
Total liabilities
$ 668
Total assets
$ 1,002
Long-term debt
$ 189
Cash and equiv.
$ 604
Goodwill
$ - -
Retained earnings
$ (1,952)
Common stock
98
Enterprise Value
$ 7,101
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
352
878
701
Receivables
- -
- -
10
Inventory
- -
- -
16
Other
21
253
385
Current assets
373
917
824
Acc. Payable
8
8
17
Debt due
3
4
4
Other
55
116
111
Current liabilities
66
128
132
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(73.44)%
- -
- -
Cash flow
240.08%
115.47%
- -
Earnings
116.41%
104.64%
- -
Dividends
- -
- -
- -
Book value
(2.88)%
106.02%
- -
Insider Trading
Type
Shares
Date
Delong Mark Jeffrey
Exempt
5,000
08/11/22
Delong Mark Jeffrey
Sale
5,000
08/11/22
Delong Mark Jeffrey
Exempt
5,000
08/11/22
Townsend Adam J.
Exempt
12,500
08/11/22
Townsend Adam J.
Sale
12,500
08/11/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
1
250
251
2021
- -
1
6
60
67
2022
14
16
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(2.25)
(1.58)
(1.81)
1.04
(4.59)
2021
(2.44)
(2.92)
(2.60)
(1.97)
(9.93)
2022
(1.42)
(1.59)
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
DR. Cedric Francois
Full-time employees:
476
City:
Waltham
Address:
100 5th Avenue
IPO:
Nov 9, 2017
Website:
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Recent News